Management of new-onset diabetes mellitus after transplantation

Postgraduate Medicine

Volumn 120, Issue 2, 2008, Pages 60-66

  Reynolds, L Raymond ^a,b   Tannock, Lisa R ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b Division of Endocrinology   (United States)

Author keywords

Cyclosporine; Diabetes mellitus, type 2; Insulin; Solid organ transplantation; Tacrolimus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; METFORMIN; MIGLITOL; NATEGLINIDE; PIOGLITAZONE; PRAMLINTIDE; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; ANTIDIABETIC AGENT;

ARTICLE; CLASSIFICATION ALGORITHM; CONSENSUS DEVELOPMENT; DIABETES CONTROL; DIABETES EDUCATION; DIABETES MELLITUS; DIABETIC DIET; DIAGNOSTIC TEST; DIARRHEA; DRUG DOSE TITRATION; EDEMA; EXERCISE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GLUCOSE INTOLERANCE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; HYPOGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; INSULIN TREATMENT; LACTIC ACIDOSIS; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; NAUSEA; NEW ONSET DIABETES MELLITUS AFTER TRANSPLANTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITION EDUCATION; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; PATIENT COUNSELING; PATIENT EDUCATION; PATIENT MONITORING; PREOPERATIVE EVALUATION; RISK FACTOR; SELF CARE; SIDE EFFECT; VOMITING; WEIGHT GAIN; ALGORITHM; DECISION TREE; KIDNEY TRANSPLANTATION; REVIEW;

ALGORITHMS; DECISION TREES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; RISK FACTORS;

EID: 54049149862     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2008.07.1792     Document Type: Article

References (29)

1. Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, Kudva YC. Posttransplantation diabetes: a systematic review of the literature. Diabetes Care. 2002;25(3):583-592.
2. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003;3(2):178-185. (Pubitemid 36323115)
3. Kiberd M, Panek R, Kiberd BA. New onset diabetes mellitus post-kidney transplantation. Clin Transplant. 2006;20(5):634-639. (Pubitemid 44383410)
4. Sulanc E, Lane JT, Puumala SE, Groggel GC, Wrenshall LE, Stevens RB. New-onset diabetes after kidney transplantation: an application of 2003 International Guidelines. Transplantation. 2005;80(7):945-952.
5. Cosio FG, Pesavento TE, Kim S, Osei K, Henry M, Ferguson RM, Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int. 2002;62(4):1440-1446.
6. Davidson J, Wilkinson A, Dantal J; International Expert Panel. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation. 2003;75(10):SS3-SS24.
7. Miles AM, Sumrani N, Horowitz R, et al. Diabetes mellitus after renal transplantation: as deleterious as non-transplant-associated diabetes? Transplantation 1998;65(3):380-384. (Pubitemid 28095966)
8. Wilkinson A, Davidson J, Dotta E, et al. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant. 2005;19(3):291-298. (Pubitemid 40711959)
9. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2008;31(suppl 1):s12-s14.
10. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109(3):433-438. (Pubitemid 38133916)
11. David DS, Cheigh JS, Braun DW Jr, Fotino M, Stenzel KH, Rubin AL. HLA-A28 and steroid-induced diabetes in renal transplant patients. JAMA. 1980;243(6):532-533. (Pubitemid 10212056)
12. Sumrani NB, Delaney V, Ding ZK, et al. Diabetes mellitus after renal transplantation in the cyclosporine era - an analysis of risk factors. Transplantation. 1991;51(2):343-347.
13. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29(8): 963-1972. (Pubitemid 44156663)
14. Jellinger PS, Davidson JA, Blonde L; ACE/AACE Diabetes Road Map Task Force. Road maps to achieve glycemic control in type 2 diabetes mellitus: ACE/AACE Diabetes Road Map Task Force. Endocr Pract 2007;13(2):260-268.
15. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2008;31(1):173-175.
16. American Diabetes Association. Standards of Medical Care in Diabetes-2008. Diabetes Care. 2008;31(suppl 1):s16-s27.
17. Hjelmesaeth J, Hartmann A, Kofstad J, Egeland T, Stenstrøm J, Fauchald P. Tapering off prednisolone and cyclosporin the first year after renal transplantation: the effect on glucose tolerance. Nephrol Dial Transplant. 2001;16(4):829-835. (Pubitemid 32257984)
18. Woodward RS, Schnitzler MA, Baty J, et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant. 2003;3(5):590 598. (Pubitemid 36612842)
19. Wyzgal J, Oldakowska-Jedynak U, Paczek L, et al. Posttransplantation diabetes mellitus under calcineurin inhibitor. Transplant Proc. 2003;35(6):2216-2218. (Pubitemid 37194369)
20. Raskin P, Allen E, Hollander P; INITIATE Study Group. Initiating insulin therapy in type 2 diabetes. Diabetes Care. 2005;28(2):260-265.
21. Hirsch IB, Bergenstal RM, Parkin CG, et al. A real-world approach to insulin therapy in primary care practice. Clin Diabetes. 2005;23(1):78-86. (Pubitemid 40965048)
22. Mayfield JA, White RD. Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function. Am Fam Physician. 2004;70(3):489-500. (Pubitemid 39045561)
23. Riddle MC, Rosenstock J, Gerich J. Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26(11):3080-3086.
24. Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007;147(6):386-399.
25. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131(4):281-303. (Pubitemid 29383658)
26. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457-2471. (Pubitemid 46919772)
27. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279-1289. (Pubitemid 41416583)
28. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes. JAMA. 2007;298(2):194-1106
29. Hollander PA, Levy P, Fineman MS, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes. Diabetes Care. 2003;26(6):784-790.